Findings suggest combined assessment of ctDNA clearance and pCR may improve risk stratification, and that the numerically highest pCR4 and EFS rates with the Dato-DXd combination warrant further evaluation.
L. McGrath, Gozde Kar, L. Bonanno et al.· Nature· 0 citations
PURPOSE
This first-in-human, nonrandomized, multicenter study investigated nelistotug (anti-CD96 monoclonal antibody [mAb]) as monotherapy (Arm A) and in combination with dostarlimab (anti-PD-1 mAb) (Arm B), and dostarlimab plus belrestotug (anti-TIGIT mAb) (Arm F) in patients with recurrent or advanced solid tumors....
L. Siu, Omid Hamid, Reva Schneider et al.· Clinical Cancer Research· 0 citations
The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.